CONMED (CNMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CONMED

NYSE•Healthcare•Medical Devices

$46.30+0.08(<0.01%)Pre-market

Market Cap

$1.39B

P/E

24.6x

P/S

1.0x

P/B

1.3x

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Cash & Earnings Quality (18/25); weakest: Growth (11/25).

Profitability11/25

Growth11/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality18/25

Strengths

Cash-backed earningsConsistent free cash flowImproving leverageConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 24.6x5y range 14.6x – 40.3x

Currently near its 16-quarter median.

P/S · 1.0x5y range 0.7x – 2.2x

Currently below its 20-quarter median.

P/B · 1.3x5y range 1.0x – 3.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 38.6% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume

Market Cap $1.39B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.37B
Q. Revenue: $343.49M
TTM EBITDA: $185.66M
TTM Op. Income: $110.32M
Q. Op. Income: $36.41M
TTM Net Income: $56.50M
Q. Net Income: $23.07M
EPS: $0.77
Shares Out.: $30.07M

$1.37B in TTM revenue grew 3.4% YoY, reaching $343.49M last quarter. TTM EBITDA of $185.66M and TTM operating income of $110.32M show growth is flowing through to the bottom line. TTM net income of $56.50M means revenue is converting into profit. Over the past year, TTM revenue is up 3% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.5%
EBITDA Margin: 16.1%
Op. Margin: 10.6%
Net Margin: 6.7%

Op. margin of 10.6% is down 0.5% YoY — costs are rising relative to revenue. Net margin at 6.7% and gross margin of 57.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 5% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 24.6x
P/S Ratio: 1.0x
P/B Ratio: 1.3x

At 24.6x P/E, the stock trades within typical market levels. P/S of 1.0x and P/B of 1.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 68% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.30B
Cash: $37.33M
Long-Term Debt: $657.05M
Book Value: $1.04B
D/E Ratio: 0.6
Debt/EBITDA: 11.8

With $2.30B in assets and $657.05M in long-term debt, D/E is 0.6and book value is $1.04B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 28% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $37.09M
TTM Free Cash Flow: $134.46M
FCF Margin: 9.8%
FCF / Net Income: 2.4

TTM FCF of $134.46M on $37.09M in operating cash flow. The FCF / Net Income ratio of 2.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 9% — an improving trend.